assay for the detection of patients with functionally defec-:ive LOL. We added serum to U937 cells in cholesterolTee incubation medium and determined the increase in cell number after a 72-h incubation at 37#{176}C by using an electronic cell counter. Sera from 10 normolipidemic individuals and from 34 patients with type Ha hyperlipoproteinemia stimulated the growth of U937 cells in proportion to the exogenous cholesterol concentration (r = 0.83, P <0.001) and the LDL-cholesterol concentration (r = 0.81, P <0.001).
However, sera from 16 patients with FDB stimulated less cell proliferation than did sera from patients with type Ila hyperlipoproteinemia with equal LDLcholesterol concentrations.
With a 15% reduction in growth as the cutoff value, this test had a sensitivity and specificity for diagnosis of FDB of 87.5% and 100%, respectively. The improved U937 monocyte proliferation assay can be used for screening hypercholesterolemic patients to detect individuals with functionally defective LDL. As shown in Fig. 2B , the correlation between these two measurements was good (r = 0.95, P <0.001).
IndexIng Terms: hypercholesterolemia/hyperlipoproteinemia/heri-
Taken together, these experiments provided evidence that the modified U937 monocyte proliferation assay has good reproducibility. During the course of this study we analyzed the sera of 10 normolipidemic individuals and 34 patients with type ila hyperlipoproteinemia.
As shown in Fig. 3A , the correlation between the number of U937 monocytes and the serum cholesterol concentration was good (r = 0.81, P <0.00 1). Cell number also correlated well with the LDLcholesterol concentration (r = 0.83, P <0.001) (Fig. 3B) with FDB. As shown in Fig. 3A 
